Biosergen

Biosergen’s antifungal drug candidate, BSG005, is the fruit of a groundbreaking effort over the last two decades by SINTEF (one of Europe’s largest independent research organizations) and the Norwegian University of Science and Technology (NTNU) to develop an improved version of Nystatin, a naturally occurring fungicidal chemical in the bacterial strain Streptomyces noursei. Work that to date has been published in more than 20 international peer reviewed scientific publications. BSG005 has been shown to have a broad spectrum of action. At similar dose levels, the drug demonstrates a three to four times in vivo potency advantage over the current standard of care for patients not responding to Azole and Echinocandin treatment. With this product profile BSG005 will fill the need for a product that offers fungicidal efficacy against a broad range of fungal strains. BSG005 appears to be without the gaps due to resistance development seen in other antifungals. Most importantly, in the GLP-tox tests and in recognized animal models it lacks the severe kidney toxicity seen with Amphotericin B formulations. BSG005 has also shown effect against resistant fungal strains and strains that have been difficult to treat with the drugs available on the market.